Topiramate (All indications) updated on 04-22-2025

Macrosomia (> 4000g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10103
R36816		 Coste (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Weight at birth (≥3500 g) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 1.03 [0.84;1.27] C
excluded (control group) 		152/477   911/2,916 1,063 477
ref
S8613
R28734		 Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 Weight at birth (≥3500 g) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.92 [0.76;1.11] C 152/477   577,097/1,710,441 577,249 477
ref
Total 1 studies 0.92 [0.76;1.11] 577,249 477
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020Coste, 2020 1 0.92[0.76; 1.11]577,2494770%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Controls unexposed, NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.92[0.76; 1.11]577,249477 -NACoste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.92[0.76; 1.11]577,249477 -NACoste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 1 Tags Adjustment   - No  - No 0.92[0.76; 1.11]577,249477 -NACoste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 1 All studiesAll studies 0.92[0.76; 1.11]577,249477 -NACoste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10103

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.92[0.76; 1.11]577,249477 -NACoste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.03[0.84; 1.27]1,063477 -NACoste (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 10.510.01.0